This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
How Do Investors React to Investment-Opportunity Shock? Evidence from the COVID-19 Pandemic and Taiwan Bio-Tech Firms (preprint)
ssrn; 2020.
Preprint
in English
| PREPRINT-SSRN | ID: ppzbmed-10.2139.ssrn.3687510
ABSTRACT
While the stock market crashed in the first quarter after the outbreak of COVID-19, this paper finds that bio-tech firms and their investors could take advantage of the COVID-19 investment opportunity and earn positive abnormal returns. Bio-tech firms earn abnormal returns of 1.63% per day—which can be translated into average capital gains of about 86.7 million NT dollars per day— around the event day on which the WHO declared COVID-19 a global emergency. Positive returns continue after the event day. Moreover, small firms and firms that enjoy greater patent originality and receiving government R&D subsidies earn higher abnormal returns.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-SSRN
Main subject:
COVID-19
Language:
English
Year:
2020
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS